REFERENCES
- PDQ Paediatric Treatment Editorial Board, National Cancer Institute, US National Institutes of Health. Late Effects of Treatment for Childhood Cancer (PDQ) Health Professional Version. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/lateeffects/healthprofessional/allpages. Accessed 20 April 2010.
- Feig SA. Second malignant neoplasms after successful treatment of childhood cancers. Blood Cells Mol Dis. 2001;27:662–666.
- Fraumeni JF Jr, Curtis RE, Edwards BK, eds. Introduction. In: New Malignancies Among Cancer Survivors: SEER Cancer Registries 1973–2000. Betheseda, MD: National Cancer Institute; 2006:1–7. NIH publication no. 05–5302.
- Gonzalez K, Noltner K, Buzin C, Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 mutations. J Clin Oncol. 2009;27:1250–1256.
- Schneider K, Garber J. Li-Fraumeni Syndrome. Gene Reviews. Bethesda, MD: National Center for Bioinformatics. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=li-fraumeni. Accessed 25 March 2010.
- Bielack S, Kempf-Bielack B, Heise U, et al, for the Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Combined modality treatment for osteosarcoma occuring as a second malignant disease. J Clin Oncol. 1999;17:1164.
- Tanaka S, Nishio S, Morioka T, Radiation-induced osteosarcoma of the sphenoid bone. Neurosurgery. 1989;25:640–643.
- Ashkan K, Pollock J, D'Arrigo C, Kitchen N. Intracranial osteosarcomas: report of four cases and review of the literature. J Neuro-Oncol. 1998;40:87–96.
- Kager L, Zoubek A, Pötschger U, et al, for the Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on Neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–2018.
- Evans DGR, Birch JM, Ramsden RT, Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43:289–294.
- Tinat J, Bougeard G, Beart-Desurmont S, Version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27:1–2.
- Bourdon JC, De Laurenzi V, Melino G, Lane D. P53: 25 years of research and more questions to answer. Cell Death Differ. 2003;10:397–399.
- Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233–240.
- Magali O, Goldgar D, Sodha N, Li-Fraumeni and related syndromes. Correlation between tumour type, family structure and TP53 genotype. Cancer Res. 2003;63:6643–6650.
- Olivier M, Eeles R, Hollstein M, The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607–614.
- International Agency for Reserch on Cancer. IARC TP53 database. Available at: http://www-p53.iarc.fr. Accessed 22 March 2010.
- Robles A, Harris C. Clinical outcomes and correlates of TP53 mutations and cancer. Perspect Biol. 2010;2(3):a001016.
- Petitjean A, Achatz MIW, Borresen-Dale AL, TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–2165.
- Pakos E, Kyzas P, Ioannidis J. Prognostic significance of TP53 tumour suppressor gene expression and mutations in human osteosarcoma. A meta-analysis. Clin Cancer Res. 2004;10:6208–6214.
- Li FP, Fraumeni JF, Mulvihill JJ, A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362.
- Gonzales KD, Buzin CH, Noltner KA, High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46:689–693.